tacrolimus extended-release capsules

FDA Drug Profile — tacrolimus, ASTAGRAF XL

Drug Details

Generic Name
tacrolimus extended-release capsules
Brand Names
tacrolimus, ASTAGRAF XL
Application Number
ANDA215012
Sponsor
Chengdu Suncadia Medicine Co., Ltd.
NDC Codes
6
Dosage Forms
CAPSULE, COATED, EXTENDED RELEASE
Routes
ORAL
Active Ingredients
TACROLIMUS

Indications and Usage

1 INDICATIONS AND USAGE Tacrolimus extended-release capsules is indicated for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants in adult patients who can swallow capsules intact [see Clinical Studies ( 14.1 ), ( 14.2 )] . Pediatric use information is approved for Astellas Pharma US, Inc.'s ASTAGRAF XL (tacrolimus extended-release capsules). However, due to Astellas Pharma US, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information. Tacrolimus extended-release capsules is a calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants in adult patients who can swallow capsules intact. ( 1 , 14.1 , 14.2 )